Merck & Co., Inc. (NYSE:MRK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Merck & Co., Inc. (NYSE:MRK) from a hold rating to a buy rating in a research report report published on Sunday morning,Wall Street Zen reports.

Several other equities research analysts have also recently commented on MRK. Wells Fargo & Company increased their price objective on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Royal Bank Of Canada lowered Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and boosted their target price for the stock from $142.00 to $150.00 in a research report on Thursday, August 20th. Weiss Ratings upgraded shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Wolfe Research raised their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $154.24.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $151.01 on Friday. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $156.92. The company has a market capitalization of $372.57 billion, a P/E ratio of 120.81, a price-to-earnings-growth ratio of 6.51 and a beta of 0.21. The firm has a 50 day moving average of $139.57 and a 200 day moving average of $125.66. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Insiders Place Their Bets

In other news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This trade represents a 24.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Institutional Trading of Merck & Co., Inc.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bullseye Investment Management LLC purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at $27,000. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at $26,000. Graney & King LLC boosted its position in Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC purchased a new position in Merck & Co., Inc. in the second quarter valued at about $41,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an update to the label for WINREVAIR (sotatercept) to include data from the Phase 3 HYPERION trial in adults recently diagnosed with pulmonary arterial hypertension. The broader clinical evidence and applicability could strengthen WINREVAIR’s commercial opportunity and reinforce Merck’s post-Keytruda growth pipeline. FDA approves WINREVAIR label update
• Positive Sentiment: Japan approved KEYTRUDA QLEX, Merck’s subcutaneous formulation of Keytruda, for all locally approved indications. Faster, more convenient administration may improve patient and clinician adoption while helping extend the value of Merck’s leading immunotherapy franchise. Japan approves KEYTRUDA QLEX
• Positive Sentiment: The European Medicines Agency’s CHMP backed the Keytruda-Padcev combination as a perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer. The recommendation expands the potential use of the combination, although final European Commission approval is still required. CHMP backs Keytruda-Padcev combination
• Neutral Sentiment: Analysts remain broadly positive, with Merck receiving an average brokerage recommendation equivalent to “Buy.” However, the reports also note that sell-side ratings can be overly optimistic and should not be treated as a standalone investment signal. Analyst recommendations for Merck
• Negative Sentiment: Some commentary characterizes MRK as overvalued and overbought after its substantial year-long outperformance, raising the risk of a near-term pullback even as pipeline progress remains encouraging. Merck valuation downgrade

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.